Literature DB >> 29518640

The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications.

Lavanya H Palavalli Parsons1, Rebecca Pedersen2, Debra L Richardson1, Kimberly A Kho3.   

Abstract

OBJECTIVE: To estimate the frequency of occult endometrial cancer in women undergoing hysterectomy for benign indications. STUDY
DESIGN: We performed a retrospective review of all patients undergoing hysterectomies for benign indications at our institution from 2006 to 2014. A departmental database was used to identify all hysterectomies performed, and institutional tumor registry was used to identify cases of endometrial carcinoma. Occult carcinomas were defined as cases with no suspicion preoperatively and histopathologic diagnosis of endometrial cancer postoperatively.
RESULTS: A total of 6981 hysterectomies were performed for benign indications. Among these, thirteen patients (0.19%) were found to have occult endometrial cancer, with an overall rate of 1 in 537 patients (95% confidence interval 1:314-1:1008). Twelve patients had stage IA and one had stage IB disease. Median age of women found to have endometrial cancer was 50 years (range 35-72 years). The median BMI was 29.8 kg/m2 (range 21.3-50.4 kg/m2). The most common indications for hysterectomy were abnormal bleeding (47%), postmenopausal bleeding (15%), adnexal mass (15%), prolapse (15%), and endometrial hyperplasia without atypia (8%). Of the postmenopausal women that had bleeding, all patients underwent evaluation of the endometrium, however 75% of samples did not have adequate amount of endometrium to be evaluated and 25% were found to have hyperplasia.
CONCLUSION: This is one of the largest single institution cohorts to examine occult malignancy. Unexpected endometrial carcinomas were found to occur in 0.19% or 1:537 (95% confidence interval 1:314-1:1008) hysterectomies for benign indications in our population. PRéCIS: Occult endometrial carcinomas are found to occur in 1:537 (0.19%) hysterectomies for benign indications.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Occult endometrial cancer; Uterine morcellation

Mesh:

Year:  2018        PMID: 29518640     DOI: 10.1016/j.ejogrb.2018.02.017

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

1.  The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry.

Authors:  Hyeong In Ha; Ha Kyun Chang; Soo Jin Park; Jiwon Lim; Young-Joo Won; Myong Cheol Lim
Journal:  Obstet Gynecol Sci       Date:  2021-08-17

2.  Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer.

Authors:  Sharon E Johnatty; Colin J R Stewart; Deborah Smith; Anthony Nguyen; John O' Dwyer; Tracy A O'Mara; Penelope M Webb; Amanda B Spurdle
Journal:  Sci Rep       Date:  2020-02-27       Impact factor: 4.379

3.  Application of Jianpi Xiaoai Recipe Combined with Cisplatin and Adriamycin in the Treatment of Endometrial Cancer and Its Effect on Disease Control Rate.

Authors:  Li Ding; Hongyu Li; Yuping Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-28       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.